Assessment of longer-term efficacy and treatment-emergent adverse events (TEAEs) in the phase 3 BELIEVE trial of luspatercept to treat anemia in patients (pts) with beta-thalassemiaH. Cario, A. T. Taher,V. Viprakasit,M. D. Cappellini, O. Hermine,P. Georgiev,K. H. M. Kuo,T. Coates,E. Voskaridou, H. K. Liew, I Pazgal-Kobrowski,G. L. Forni, S. Perrotta,A. Khelif,A. Lal,A. Kattamis,F. Shah, J. Porter,A. Laadem,J. K. Shetty,W-L Kuo,J. Zhang, D. Miteva, T. Zinger, D. Sinsimer, C. U. Louis,A. PigaONCOLOGY RESEARCH AND TREATMENT（2020）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
